The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.49BCNY
819.27M · vs all stocks (USD)
Updated Sep 20, 2026
Revenue (TTM)
2.13BCNY
317.76M · vs all stocks (USD)
Updated Sep 20, 2026
Profit Margin
-1.67%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Beta
0.2030x
vs all stocks
Updated Sep 20, 2026
52-Week Change
-22.99%
vs all stocks
Updated Sep 20, 2026
Market Capitalization
5.49BCNY
819.27M · vs all stocks (USD)
Updated Sep 20, 2026
Enterprise Value
5.64BCNY
841.96M · vs all stocks (USD)
Updated Sep 20, 2026
Forward P/E
10.44x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Sales (TTM)
2.58x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Price to Book (MRQ)
0.8703x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to Revenue
2.65x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Enterprise to EBITDA
16.04x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 14.6×.Updated Sep 20, 2026
Gross Margin
56.90%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Profit Margin
-1.67%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Margin
0.30%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Assets (TTM)
-0.50%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Return on Equity (TTM)
-0.76%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Revenue (TTM)
2.13BCNY
317.76M · vs all stocks (USD)
Updated Sep 20, 2026
Revenue per Share (TTM)
3.55CNYUpdated Sep 20, 2026
Quarterly Revenue Growth
-1.10%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Gross Profit (TTM)
1.18BCNY
176.14M · vs all stocks (USD)
Updated Sep 20, 2026
EBITDA (TTM)
386.43MCNY
57.66M · vs all stocks (USD)
Updated Sep 20, 2026
Net Income (TTM)
-35.61MCNY
-5.31M · vs all stocks (USD)
Updated Sep 20, 2026
Quarterly Earnings Growth (YoY)
151.10%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Operating Cash Flow (TTM)
699.93MCNY
104.44M · vs all stocks (USD)
Updated Sep 20, 2026
Levered Free Cash Flow (TTM)
185.64MCNY
27.70M · vs all stocks (USD)
Updated Sep 20, 2026
5-Year Average Dividend Yield
1.78%
vs all stocks
Updated Sep 20, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Sep 20, 2026
Minority Interest (Equity)
30.03MCNYFY2025 · Dec 31, 2025
Revenue
2.17BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
890.54MCNYFY2025 · Dec 31, 2025
Gross Profit
1.28BCNYFY2025 · Dec 31, 2025
Operating Income
54.76MCNY
8.17M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-99.54MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-58.04MCNYFY2025 · Dec 31, 2025
Net Income
-41.49MCNYFY2025 · Dec 31, 2025
EBIT
-78.00MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
386.43MCNYFY2025 · Dec 31, 2025
Research & Development
317.94MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
297.75MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
26.89MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
6.86MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
21.54MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.0593CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.0593CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
604.17MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
604.17MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-41.49MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
5.67MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
118.21MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-603.19MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
659.41MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-41.49MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
27.66MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
202.63MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-70.58MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-721.40MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-152.58MCNYFY2025 · Dec 31, 2025
Sale of Investments
175.40MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-24.01MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-722.59MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
817.64MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-490.94MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-83.74MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-36.82MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
206.14MCNYFY2025 · Dec 31, 2025
Shares Outstanding
604.67MSharesUpdated Sep 20, 2026
Float Shares
369.95MSharesUpdated Sep 20, 2026
% Held by Insiders
37.62%
vs all stocks
Updated Sep 20, 2026
% Held by Institutions
4.43%
vs all stocks
Updated Sep 20, 2026
Total Cash (MRQ)
814.29MCNY
121.51M · vs all stocks (USD)
Updated Sep 20, 2026
Total Cash per Share (MRQ)
1.35CNYUpdated Sep 20, 2026
Total Debt (MRQ)
940.93MCNY
140.41M · vs all stocks (USD)
Updated Sep 20, 2026
Total Debt to Equity (MRQ)
0.1485x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Current Ratio (MRQ)
3.99x
vs Diagnostics & Research peers
Updated Sep 20, 2026
Book Value per Share (MRQ)
10.43CNYUpdated Sep 20, 2026
Total Assets
7.99BCNY
1.19B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
3.23BCNYFY2025 · Dec 31, 2025
Total Liabilities
1.69BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
4.77BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
635.53MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.05BCNYFY2025 · Dec 31, 2025
Cash
659.41MCNYFY2025 · Dec 31, 2025
Cash Equivalents
7.78MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
667.19MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
50.18MCNYFY2025 · Dec 31, 2025
Accounts Receivable
1.14BCNYFY2025 · Dec 31, 2025
Inventory
849.13MCNYFY2025 · Dec 31, 2025
Accounts Payable
208.67MCNYFY2025 · Dec 31, 2025
Short-term Debt
420.10MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
8.76MCNYFY2025 · Dec 31, 2025
Long-term Debt
526.17MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
6.75MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
604.67MCNYFY2025 · Dec 31, 2025
Retained Earnings
3.77BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
6.31BCNY
940.93M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
7.87CNYUpdated Sep 20, 2026
52-Week High
14.20CNYUpdated Sep 20, 2026
52-Week Change
-22.99%
vs all stocks
Updated Sep 20, 2026
Beta
0.2030x
vs all stocks
Updated Sep 20, 2026
50-Day MA
9.17CNYUpdated Sep 20, 2026
200-Day MA
10.33CNYUpdated Sep 20, 2026
Avg 10-Day Volume
3.57MSharesUpdated Sep 20, 2026
Avg 30-Day Volume
6.80MSharesUpdated Sep 20, 2026
Diluted EPS (TTM)
-0.0600CNYUpdated Sep 20, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable